Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

• Published in: Journal of thoracic oncology Vol. 13; no. 12; pp. 1818 - 1831
• Main Authors: Blumenthal, Gideon M., Bunn, Paul A., Chaft, Jamie E., McCoach, Caroline E., Perez, Edith A., Scagliotti, Giorgio V., Carbone, David P., Aerts, Hugo J.W.L., Aisner, Dara L., Bergh, Jonas, Berry, Donald A., Jarkowski, Anthony, Botwood, Nicholas, Cross, Darren A.E., Diehn, Max, Drezner, Nicole L., Doebele, Robert C., Blakely, Collin M., Eberhardt, Wilfried E.E., Felip, Enriqueta, Gianni, Luca, Keller, Steven P., Leavey, Patrick J., Malik, Shakun, Pignatti, Francesco, Prowell, Tatiana M., Redman, Mary W., Rizvi, Naiyer A., Rosell, Rafael, Rusch, Valerie, de Ruysscher, Dirk, Schwartz, Lawrence H., Sridhara, Rajeshwari, Stahel, Rolf A., Swisher, Stephen, Taube, Janis M., Travis, William D., Keegan, Patricia, Wiens, Jacinta R., Wistuba, Ignacio I., Wynes, Murry W., Hirsch, Fred R., Kris, Mark G.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2018; Copyright by the International Association for the Study of Lung Cancer
• Subjects: Induction chemotherapy; Neoadjuvant therapy; Pathologic response; Preoperative therapy; Resectable lung cancer; Neoadjuvant therapy; Resectable lung cancer; Induction chemotherapy; Preoperative therapy; Pathologic response
• ISSN: 1556-0864; 1556-1380; 1556-1380
• DOI: 10.1016/j.jtho.2018.09.017

This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes. There are unique opportunities and challenges with the neoadjuvant approach to drug development. To achieve more rapid knowledge turns, study designs, endpoints, and definitions of pathologic response should be standardized and harmonized. Continued dialogue with all stakeholders will be critical to design and test novel induction strategies, which could expedite drug development for patients with early lung cancer who are at high risk for metastatic recurrence.